Regulatory Affairs
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Navigate global pharma regulatory affairs. Get expert insights on FDA, EMA, and global compliance for drug approvals, market access, and R&D strategy.
Showing 1–12 of 13 articles
Quick answer
NovaPharmaNews Regulatory Affairs hub for NMPA covers 13 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Australia's TGA Section 41HD Emergency Medical Device Import Approvals: Complete Guide for Healthcare Providers
Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit Ruling
a2 Milk Company Recalls Three Batches of a2 Platinum Infant Formula Due to Health Risk Concerns
TGA Issues Guidance on Combination and Boundary Products for Pharmaceutical Companies in APAC
EirGenix Expands Japan Biosimilar Strategy at CPHI Japan 2026 Amid Regulatory Support
China Clinical Trial Regulations: Key Insights on NMPA Reforms 2024
Aquestive Therapeutics Faces Class Action Lawsuit Over Anaphylm Drug Approval Timeline Claims
Australia's TGA Updates Comprehensive Biologicals Regulatory Framework for Advanced Therapies
Australia's TGA Updates Therapeutic Sunscreen Regulatory Framework for Enhanced Consumer Protection
Australia's TGA Updates Medicinal Cannabis Access Guidelines for Pediatric Patients Under Special Access Scheme
Australia's TGA Updates Over-the-Counter Medicine Registration Guidelines for Pharmaceutical Companies
Australia's TGA Expands Therapeutic Vaping Access Through Pharmacy Channels with New Regulatory Framework
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.